Inhibitors of the ras oncogene as therapeutic targets (Q35038751)

5 August 2017

title

Inhibitors of the ras oncogene as therapeutic targets (English)

1 reference

5 August 2017

1

Irene M Ghobrial

1 reference

5 August 2017

Alex A Adjei

2

1 reference

5 August 2017

publication date

1 October 2002

1 reference

Hematology / Oncology Clinics of North America

5 August 2017

language of work or name

1 reference

1 reference

5 August 2017

volume

16

1 reference

5 August 2017

issue

5

1 reference

5 August 2017

page(s)

1065-1088

1 reference

publication type of scholarly work

5 August 2017

review article

1 reference

Blocking oncogenic Ras signaling for cancer therapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Ras signaling pathway proteins as therapeutic targets

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

1 reference

7 January 2021

Genetics of RAS signaling in C. elegans

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

The Ras branch of small GTPases: Ras family members don't fall far from the tree

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Increasing complexity of Ras signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Regulation of the mevalonate pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Protein prenylation: molecular mechanisms and functional consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Protein isoprenylation and methylation at carboxyl-terminal cysteine residues

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

The gamma subunit of transducin is farnesylated

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Structure and biological activity of human homologs of the raf/mil oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Clinical evaluation of biologically targeted drugs: Obstacles and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Enzymatic modification of proteins with a geranylgeranyl isoprenoid

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Rab geranylgeranyl transferase catalyzes the geranylgeranylation of adjacent cysteines in the small GTPases Rab1A, Rab3A, and Rab5A

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Ras biochemistry and farnesyl transferase inhibitors: a literature survey

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Signal-transduction therapy. A novel approach to disease management

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Signaling by integrin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

How does the G protein, Gi2, transduce mitogenic signals?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Involvement of ras p21 protein in signal-transduction pathways from interleukin 2, interleukin 3, and granulocyte/macrophage colony-stimulating factor, but not from interleukin 4

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

p21ras activation via hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation of p21ras GTPase-activating protein

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Proteins regulating Ras and its relatives

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Regulation of the Ras signalling network

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Protein modules and signalling networks

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Identification of a specific Ins(1,3,4,5)P4-binding protein as a member of the GAP1 family

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

A human protein selected for interference with Ras function interacts directly with Ras and competes with Raf1

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Identification and characterization of the neurofibromatosis type 1 protein product

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Transformation of mammalian cells by constitutively active MAP kinase kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Identification of AF-6 and canoe as putative targets for Ras.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Activation of Raf as a result of recruitment to the plasma membrane

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

The complexity of Raf-1 regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

1 reference

7 January 2021

Membrane recruitment of Raf-1 is not the only function of Ras in Raf-1 activation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Raf revealed in life-or-death decisions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Definition of the human raf amino-terminal regulatory region by deletion mutagenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Mutational activation of c-raf-1 and definition of the minimal transforming sequence

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Regulation of Ras-mediated signalling: more than one way to skin a cat.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Raf-1 protein kinase is required for growth of induced NIH/3T3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Interaction of activated Ras with Raf-1 alone may be sufficient for transformation of rat2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Cooperating oncogenes converge to regulate cyclin/cdk complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Raf-Induced Proliferation or Cell Cycle Arrest Is Determined by the Level of Raf Activity with Arrest Mediated by p21Cip1

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

A role for Rho in Ras transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Rho GTPases and the Actin Cytoskeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Phosphoinositide kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Regulation of cell death protease caspase-9 by phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

eIF4E activity is regulated at multiple levels

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

A role for the Ral guanine nucleotide dissociation stimulator in mediating Ras-induced transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Colocalization of Ras and Ral on the membrane is required for Ras-dependent Ral activation through Ral GDP dissociation stimulator

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

ralGDS family members interact with the effector loop of ras p21.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Inhibitors of farnesyl protein transferase. Synthesis and biological activity of amide and cyanoguanidine derivatives containing a 5,11-dihydro[1]benzthiepin, benzoxepin, and benzazepin [4,3-b]pyridine ring system

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Ras-dependent activation of the small GTPase Ral

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Ras-dependent growth factor regulation of MEK kinase in PC12 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

The regulation of AP-1 activity by mitogen-activated protein kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

1 reference

7 January 2021

Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Prevalence of ras gene mutations in human colorectal cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Genetic alterations during colorectal-tumor development

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Concepts in Ras-directed therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Mechanism of activation of a human oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

ras oncogenes: their role in neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Reovirus therapy of tumors with activated Ras pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Novel pharmacological agents in clinical development for solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Current status of clinical trials of farnesyltransferase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Aggresome formation by anti-Ras intracellular scFv fragments. The fate of the antigen-antibody complex

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Diverting a protein from its cellular location by intracellular antibodies. The case of p21Ras

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Re: Blocking Oncogenic Ras Signaling for Cancer Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Biological effects and mechanism of action of farnesyl transferase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900050-3

7 January 2021

10.1016/S0889-8588(02)00050-3

Identifiers

DOI

1 reference

5 August 2017

1 reference